— Know what they know.
Not Investment Advice
Also trades as: 4516.T (JPX) · $vol 8M · NPPNY (OTC) · $vol 0M

NPNKF OTC

Nippon Shinyaku Co., Ltd.
1W: +0.0% 1M: -1.7% 3M: -26.4% YTD: -24.2% 1Y: +inf% 3Y: -57.1% 5Y: -72.7%
$23.50
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 46 · $1.6B mcap · 47M float · 0.0000% daily turnover · Short 83% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.6B
52W Range21-38.01
Volume81
Avg Volume11
Beta-0.32
Dividend$0.78
Analyst Ratings
0 Buy 2 Hold 0 Sell
Consensus Hold
Company Info
CEOToru Nakai
Employees2,309
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2021-09-03
14, Nishinosho-Monguchi-cho
Kyoto, KY 601-8550
JP
81 7 5321 1111
About Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms